Merck’s Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?
Merck’s Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?
5 questions ESMO cancer drug data might answer
5 questions ESMO cancer drug data might answer
AstraZeneca’s Imfinzi tees up small cell lung cancer fight with Roche
AstraZeneca’s Imfinzi tees up small cell lung cancer fight with Roche
Celgene dips out of deals ahead of mega-merger
Celgene dips out of deals ahead of mega-merger
All the ASCO skinny: Lynparza’s pancreatic win, Amgen’s KRAS spotlight, Merck’s history-busting and more
All the ASCO skinny: Lynparza’s pancreatic win, Amgen’s KRAS spotlight, Merck’s history-busting and more
5 novel immuno-oncology targets to know before ASCO
5 novel immuno-oncology targets to know before ASCO
Bristol-Myers’ Opdivo fails brain tumor test again, this time in new patients
Bristol-Myers’ Opdivo fails brain tumor test again, this time in new patients
Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
AACR: BMS, clinging to Opdivo’s lung cancer share, highlights long-term data
AACR: BMS, clinging to Opdivo’s lung cancer share, highlights long-term data
Top 15 Best-Selling Drugs of 2018
Top 15 Best-Selling Drugs of 2018
Bristol-Myers Squibb Going All out to Sell Celgene Deal
Bristol-Myers Squibb Going All out to Sell Celgene Deal
New Tools to the 4 Pillars of Cancer Treatment: Biomarker Testing and Chronic Cancers
New Tools to the 4 Pillars of Cancer Treatment: Biomarker Testing and Chronic Cancers
Top 10 Immuno-Oncology Startups
Top 10 Immuno-Oncology Startups
J&J Earns Spot in Fortune’s Top 50 Most Respected Companies
J&J Earns Spot in Fortune’s Top 50 Most Respected Companies
Asco-GU 2019 – checkpoint blockers might not be created equal after all
Asco-GU 2019 – checkpoint blockers might not be created equal after all
Marketing Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early
Marketing
Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early
